Effects of <i>CYP3A5</i> Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation

• Main Authors: Daniel N. Marco (Author), Mònica Molina (Author), Ana-María Guio (Author), Judit Julian (Author), Virginia Fortuna (Author), Virginia-Lucila Fa (Author), María-Queralt Salas (Author), Inés Monge-Escartín (Author), Gisela Riu-Viladoms (Author), Esther Carcelero (Author), Joan Ramón Roma (Author), Noemí Llobet (Author), Jordi Arcarons (Author), María Suárez-Lledó (Author), Laura Rosiñol (Author), Francesc Fernández-Avilés (Author), Montserrat Rovira (Author), Mercè Brunet (Author), Carmen Martínez (Author)
• Format: Book
• Published: MDPI AG, 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Tacrolimus (Tac) is pivotal in preventing acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT). It has been reported that genetic factors, including <i>CYP3A5</i>*<i>3</i> and <i>CYP3A4*</i>22 polymorphisms, ha...